Updates are available Correction dated 2022-02-26
Click to view Correction: https://doi.org/10.1007/s11916-022-01027-9
-
Authors
Marathe, Anuj https://orcid.org/0000-0002-0387-821X
Allahabadi, Sameer
Abd-Elsayed, Alaa
Saulino, Michael
Hagedorn, Jonathan M.
Orhurhu, Vwaire
Karri, Jay
- License Information
-
More Information
Article History
Accepted: 18 October 2021
First Online: 11 December 2021
Change Date: 26 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11916-022-01027-9
Compliance with Ethical Standards
:
: Michael Saulino is a clinical investigator for Flowonix, Medtronic, and Bioness, receives in-kind speaker’s fees from Ipsen and Medtronic, and holds two neuromodulation patents. Jonathan M. Hagedorn is a consultant for Abbott, Boston Scientific, Nevro, and Speranza Therapeutics. Alaa Abd-Elsayed is a consultant for Medtronic, StimWave, Avanos, and Sollis. PhR is supported by Clinical Mandate from the Belgian Foundation against Cancer (Stichting tegen Kanker) and receives speaking and consultancy fees from MSD Belgium. GC and JW declare no conflict of interest.
